0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover0.00%IV-92.64%PremiumAug 9, 2024Expiry Date10.82Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Novavax Stock Discussion
★★ Key Points Summary
Sanofi Partnership Progress:
- Partnership Terms: Novavax's collaboration with Sanofi involves an upfront payment and equity investment totaling $570 million, with potential milestone payments reaching $700 million. The deal includes long-term royalties from COVID-19 vaccine and Matrix-M adjuvant sales.
- Commercialization Transition: Sanofi will take over commercialization in 2025, allowing Novavax to shift focus to research...
imagine the pain
As reported by Forbes. The Novavax updated vaccine is much superior to the the moderna and Pfizer. It creates 48x antibodies while Moderna and Pfizer created 7x or 8x only.
Why? The answer is imprinting. Once you get a shot of Wuhan mRNA vaccine the body remembers it and will always produce antibodies agai...
dipping
down
againnnnn
"We’re all in on AI. We want to become the first biopharma company powered by AI at scale" -
"We invest in AI that makes a difference for our people, patients, and partners" - #sanofi
Novavax
- 2021 Gets $1.6 billion government grant to develop its COVID shot
- Stock soars over $280
- 2024 - Sanofi is taking a 4.9% equity position in Novavax with 1.2 billion dollar deal with $500 Million up front.
- Malaria WHO Approved & rolled...
Vivek Shinde, the Vice President of Clinical Development at Novavax, recently discussed the company's innovative use of machine learning (ML) tools to improve the process of determining vaccine doses. Traditionally, this process has been quite crude and simplistic. However, by employing ML, Novavax was able to vary different components of a multi-component vaccine and use ML to understand the entire surface of response in a three-dimensional space.
In particular...
Novavax recently participated in Premier's Breakthroughs 2024 conference, held from July 23-25 at the Gaylord National Resort & Convention Center in National Harbor, Maryland. This influential healthcare conference brought together industry leaders to discuss advancements in healthcare, including supply chain success, health equity, artificial intelligence, and clinical risk reduction.
At the conference, Novavax's President and COO, John Trizzino, emphasized the...
No comment yet